NBI-98854
NBI-98854-1202
Phase 3 small_molecule completed
Quick answer
NBI-98854 for Tardive Dyskinesia is a Phase 3 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 6 ClinicalTrials.gov record(s).
Program details
- Company
- NEUROCRINE BIOSCIENCES INC
- Indication
- Tardive Dyskinesia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed